Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
· pharming group n.v.
Source Summary
Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2026.
Advertisement